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ABSTRACT  
   
Fusion proteins that specifically interact with biochemical marks on chromosomes 
represent a new class of synthetic transcriptional regulators that decode cell state information 
rather than deoxyribose nucleic acid (DNA) sequences. In multicellular organisms, information 
relevant to cell state, tissue identity, and oncogenesis is often encoded as biochemical 
modifications of histones, which are bound to DNA in eukaryotic nuclei and regulate gene 
expression states. In 2011, Haynes et al. showed that a synthetic regulator called the Polycomb 
chromatin Transcription Factor (PcTF), a fusion protein that binds methylated histones, reactivated 
an artificially-silenced luciferase reporter gene. These synthetic transcription activators are derived 
from the polycomb repressive complex (PRC) and associate with the epigenetic silencing mark 
H3K27me3 to reactivate the expression of silenced genes. It is demonstrated here that the duration 
of epigenetic silencing does not perturb reactivation via PcTF fusion proteins. After 96 hours PcTF 
shows the strongest reactivation activity. A variant called Pc2TF, which has roughly double the 
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PREFACE 
 Chapter 2 of this document is a published article in which I was a co-author. The citation 
and author contributions are described below. All authors provided permission for the use of this 
publication. 
Tekel S, Vargas D, et al. (2018) Tandem Histone-Binding Domains Enhance the Activity of a 
Synthetic Chromatin Effector.  ACS Synthetic Biology 7(3), 842-852 
In the cited article I participated by cloning mammalian expression constructs and 
performing transfections, flow cytometry and imaging, dox-mediated silencing, luciferase activity 
assays, and RT-qPCR. This is all culminated in Figure 2.5 in chapter 2. I was the only co-author 
member who had experience with expressing PcTF in mammalian tissue culture and with 
analyzing PcTF expression with fluorescence microscopy. We showed that the synthetic 
transcriptional activators were only effective after the cells had been silenced and supports that 
they function by binding to the H3K27me3 as they were designed to do, this can be seen in 
Figure 2.5 D. 
S.T. was responsible for building bacterial expression constructs, produce purified 
protein, perform protein validation, and execute the TXTL experiments. S.T. and L.S designed 
and executed ELISA and spot array analysis. K.A.H. performed Western blotting, mammalian 














Chromatin’s function in living eukaryotic organisms is to package the long stretches of DNA 
which plays a role during cell division, regulation of gene expression and is vital during 
development. This complex consists of DNA and protein and can be found in found in two types of 
configurations. Euchromatin is the form of chromatin that is decompacted and is accessible to DNA 
binding proteins such as RNA polymerase which allows for different level of transcriptional activity 
(Human Genome Sequencing Consortium, 2004). The other version of chromatin is 
heterochromatin which, is a tightly compacted or “closed” form and is generally not accessible to 
DNA binding proteins and hinders gene expression. 
 Heterochromatin can also be described in two different forms as well, constitutive 
heterochromatin and facultative heterochromatin. Constitutive heterochromatin is typically found in 
pericentric regions of chromosomes and on the telomeres (Grewal, 2007; Grunstein, 1998). These 
regions are mostly absent of protein coding sequences but do contain a few, these regions are also 
very stable and include repetitive noncoding sequences (Kent, 2001). Facultative heterochromatin 
is mostly transcriptional silent; however it has the potential to convert from heterochromatin to 
euchromatin. This means the condensed chromatin can decondense and allow transcription for 
developmental stages or specific cell cycles (Trojer, 2007).  
 Overall the chromatin complex, which consists of DNA and protein, is organized into basic 
subunits called nucleosomes.  Nucleosomes are composed of 147 base pairs of DNA wrapped 
around an octamer of histone proteins. The main feature of focus for this research project is the 
histone tails, which is unstructured and can be chemically modified with activating or silencing 
marks. The states of chromatin mentioned before are reliant on these modifications and the spacing 
between the nucleosomes. In our work we focus the manipulation of the facultative heterochromatin 
state regulated by Polycomb group (PcG) proteins and synthetic derivatives. 
  
 
  2 
1.2 Polycomb Group Proteins 
Polycomb Group Proteins (PcG) are transcriptional repressors responsible for epigenetically 
modifying chromatin which helps in the establishment and maintenance of cell fates. They play a 
vital role in both stem cell self-renewal and in cancer development (Sauvageau, 2010). The latter 
will be discussed in further detail. 
Nearly 40 years ago Pamela Lewis first identified a Drosophila gene coding for a protein called 
Polycomb and shortly thereafter Ed Lewis described Polycomb as a “regulator of regulators” 
proposing its importance in the control of body segmentation in Drosphila through the repression 
of Hox genes (Lewis, P. 1947; Lewis, E. 1978). Since then these genes have been identified as 
global epigenetic transcriptional repressors (Schwartz, 2007).  
There have been two main PcG complexes identified in mammals; Polycomb Repressive  
Complex 1 and 2 (PRC1, PRC2). The core proteins in PRC1 are made up of PCGF, CBX, PHC, 
SCML, and RING1 (Figure 1.1)(Levine, 2002; Wang, 2004) There are five chromodomain-
containing CBX family proteins, CBX2,4, 6, 7, and 8, associated with PRC1 and are found in 
different subnuclear region (Vincenz, 2008). CBX8 was originally thought to have a weak affinity 
for methylated histones in vitro, however, was later determined to be a major driver of chromatin 
association (Connelly, 2019).  The core of PRC2 is made up of SUZ12, an isoform of EED, and 
either EZH1 or EZH2. EZH is responsible for the catalyzation of the trimethylation of lysine 27 of 
histone 3 (H3K27me3) which is the main epigenetic mark that will be studied in this thesis (Figure 
1.2)(Cao, R. 2002; Cao, R. 2004).   
1.3 Mechanism of Polycomb-Mediated Silencing 
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Figure 1.1 Model Showing the Mechanism of Polycomb-Mediated Silencing. (A) The EZH1/2 
subunit of PRC2 trimethylates the H3K27. (B) Trimethylation of H3K27 acts as a docking site for 
PRC1 causing the gene silencing.  
There are several different ways that PRC1 and 2 interact and read and write the epigenetic 
silencing code, here we will focus on the canonical mechanism for Polycomb-mediated silencing 
due to its importance in understanding in later chapters. PRC2 has the ability to both write and bind 
to the silencing mark histone 3 lysine 27 trimethylation (H3K27me3) with EZH1/2 responsible for 
the writing and EED with the ability to bind to the H3K27me3 mark (Figure 1.1). PRC1 also has the 
ability to bind to H3K27me3 with the CBX subunit (Fischle, 2003). After recruitment, the EZH1/2 
subunit of PRC2 “writes” or catalyzes the trimethylation of H3K27me3 (Figure 1.1 A). The 
subsequent recruitment of PRC1 results in the binding of the chromodomain of CBX to the 
H3K27me3 (Figure 1.1 B) (Francis, 2004; Zhou, 2008). The localization of these PcG proteins and 
the H3K27me3 helps compact the nucleosome and lead the gene silencing and blocking proteins 
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CHAPTER 2 
TANDEM HISTONE-BINDING DOMAINS ENHANCE THE ACTIVITY OF A SYNTHETIC 
CHROMATIN EFFECTOR 
 
 Fusion proteins that specifically interact with biochemical marks on chromosomes 
represent a new class of synthetic transcriptional regulators that decode cell state information 
rather than DNA sequences. In multicellular organisms, information relevant to cell state, tissue 
identity, and oncogenesis is often encoded as biochemical modifications of histones, which are 
bound to DNA in eukaryotic nuclei and regulate gene expression states. We have previously 
reported the development and validation of the “polycomb-based transcription factor” (PcTF), a 
fusion protein that recognizes histone modifications through a protein− protein interaction between 
its polycomb chromodomain (PCD) motif and trimethylated lysine 27 of histone H3 (H3K27me3) at 
genomic sites. We demonstrated that PcTF activates genes at methyl-histone-enriched loci in 
cancer-derived cell lines. However, PcTF induces modest activation of a methyl-histone associated 
reporter compared to a DNA-binding activator. Therefore, we modified Pc2TF to enhance its binding 
avidity. Here, we demonstrate the activity of a modified regulator called Pc2TF, which has two 
tandem copies of the H3K27me3-binding PCD at the N-terminus. PcTF has a smaller apparent 
dissociation constant value in vitro and shows enhanced gene activation in HEK293 cells compared 
to PcTF. These results provide compelling evidence that the intrinsic histone-binding activity of the 
PCD motif can be used to tune the activity of synthetic histone-binding transcriptional regulators. 
2.1 Introduction 
 The discovery of histone post-translational modifications (PTMs) and the peptides that 
specifically interact with these marks has enabled scientists and cell engineers to manipulate 
chromatin, the DNA−protein structure that regulates gene expression states in eukaryotic cells. 
Structure-based models have informed targeted knock-down of chromatin subunits and the rational 
design of low molecular weight inhibitor compounds (reviewed in ref Tekel, 2017). DNA-binding 
domains fused with structural chromatin proteins and histone-modifying enzymes have been used 
to generate ectopic chromatin conformations at specific loci (Cano-Rodriguez, 2016; Park 2016). 
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Until recently, scientists had not yet leveraged PTM-binding peptides from natural effector proteins 
to “read” the rich biological information encoded in histone marks in living cells. Peptides that 
recognize specific histone PTM signals are essential for synthetic systems that integrate epigenetic 
regulatory signals. In order to use PTM- binding peptides in synthetic fusion proteins, the peptides 
must be portable, that is, maintain their intrinsic function within a new protein sequence. Early 
studies established important foundational knowledge by demonstrating that the interaction of the 
chromodomain motif (CD) with trimethylated histone H3 lysine 27 (H3K27me3) is an intrinsic 
activity that is maintained by the CD in the context of recombinant, fusion proteins (Platero, 1995; 
Messmer, 1992). Other protein folds including the bromodomain (BRD) and plant homeodomain 
finger (PHD) function as isolated peptides (Filippakopoulos, 2012; Ruthenburg, 2011; Gatchalian, 
2013) and within fusion proteins (Ruthenburg, 2011; Wang, 2015) to specifically interact with 
acetylated histone lysines (BRD) and H3K4me3 (PHD).  
We constructed the polycomb-based transcription factor (PcTF) using a histone PTM-
binding motif from the natural protein CBX8 (Haynes, 2011). The CBX8 effector protein binds to 
histone H3 trimethylated at lysine 27 (H3K27me3) through its N- terminal polycomb chromodomain 
(PCD) and establishes a silenced transcriptional state. Expression of PcTF, an artificial 
transcriptional activator with an N-terminal PCD, mCherry tag, and C-terminal VP64 activation 
domain, led to increased expression of H3K27me3-enriched genes in three different cancer-
derived cell lines (Nyer, 2017). These results show promise for designing transcription factors that 
can read chromatin marks to rewire aberrant epigenetic programming. However, binding affinities 
observed in vitro for isolated PCDs is poor, reported as 5 to >500 μM, (Bernstein, 2006; Fischle, 
2003) compared to DNA-binding domains with target affinities in the pico- to nanomolar range such 
as transcription activator-like effectors (TALEs, ∼3−220 nM), (Meckler, 2013) zinc fingers 
(∼0.01−16 nM), (Jantz, 2010; Greisman, 1997) and clustered regularly interspaced short 
palindromic repeats (CRISPR)/CRISPR- associated domains (Cas) (∼0.5 nM) ( Sternberg, 2014). 
In other work, we observed stronger gene upregulation when mCherry-VP64 was targeted to a 
promoter via a Gal4 DNA binding domain compared to the PCD histone-binding domain (Haynes, 
2011). PcTF- mediated gene activation is dose dependent (Nyer, 2017), and high PcTF expression 
  6 
levels are required for optimal activity. This limits the usefulness of PcTF for therapeutic 
applications where barriers to delivery severely limit the number of proteins that ultimately reach 
the nuclei of target cells. Although pharmacokinetic barriers to DNA and protein delivery in vivo are 
not trivial, increasing the effective dose of PcTF could significantly advance this technology toward 
clinical use.  
The appearance of tandem histone binding domains within natural proteins suggests that 
the performance of histone- binding regulators can be customized and tuned through multivalency, 
defined as contact with more than one histone PTM via multiple domains (reviewed in refs Park, 
2016; Ruthernburg, 2007; Su, 2016). Multivalent chromatin proteins can engage adjacent PTMs 
within a single histone tail, such as K4me3 and R8me2 on histone H3 bound by Spindlin1 (Su, 
2014) or K5ac and K12ac on histone H4 bound by TAFII250 (Jacobson, 2000). PTM targets can 
also reside on two distinct histone tails, such as H4K16ac and H3K4me3 bound by BPTF 
(Ruthenburg, 2011). Dual recognition of histone PTMs is accomplished by tandem protein motifs 
within the histone- binding protein. Comparisons of natural mono- and divalent proteins, (Voigt, 
2011) as well as histone peptide on- and off-target binding studies, (Su, 2014; Oliver, 2012) have 
produced compelling evidence that tandem motifs contribute to avidity and specificity. The idea that 
combinatorial avidity allows proteins to read a “histone code” has been the topic of some 
controversy. Until recently, multivalency had not been demonstrated using a rationally designed 
composition of binding domains. Tandem histone binding domains have been used to design 
protein probes to fluorescently label regions that are enriched for specific histone modifications 
(Sanchez, 2017; Delachat, 2018). To date, multivalency has not been used to design a 
transcriptional regulator and tandem PCDs have not been reported. In order to compensate for the 
modest affinity of the CBX8 PCD (Bernstein, 2006) for its target, we added a second copy of 
H3K27me3-binding PCD to the N-terminus of PcTF to build Pc2TF. Here, we demonstrate that 
Pc2TF shows stronger avidity for H3K27me3 in vitro. This activity corresponds with enhanced 
activation of a H3K27me3-repressed gene in cultured cells. Our results have important implications 
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for building and tuning fusion proteins that target sites of polycomb-mediated silencing, which plays 
a central role in cancer and stem cell plasticity. 	
2.2 Results and Discussion 
 
Figure 2.1. Three-dimensional model layout to show the plausibility of Pc2TF binding to adjacent 
H3K27me3 marks. (A) PCD (CBX8) in complex with trimethyl lysine (PDB 3I91) (Kaustov, 2011). 
Three residues form a hydrophobic cage and surround the Kme3 moiety (inset). (B) H3K27me3 
recognition by synthetic fusion proteins that carry a single or tandem PCD domains (PcTF and 
Pc2TF, respectively). The 3D rendering was composed in the PyMOL Molecular Graphics System, 
version 1.3, Schrödinger, LLC (https://www.pymol.org), using data for CBX8/H3K9me3 (PDB 
4X3K) (Ren, 2015) and a whole nucleosome assembly (PDB 5AV8) (Ren, 2015; Wakamori, 2015) 
from the Protein Data Bank.  
2.2.1 Design of a Bivalent Synthetic Chromatin-Based Transcriptional Regulator.  
We designed the Pc2TF protein to simultaneously recognize two copies of the histone post- 
translational modification H3K27me3. The polycomb chromo-domain motif (PCD) consists of three 
β strands packed against a C-terminal α helix and a hydrophobic pocket formed by three aromatic 
residues that interact with a methyl-lysine side chain (Fischle, 2003; Min, 2003) (Figure 2.1 A). The 
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arrangement of histones within the nucleosome octamer suggests that Pc2TF might bind adjacent 
trimethylated H3K27 residues. A single nucleosome includes eight individual histone proteins. The 
central tetramer contains two copies of histone H3 and H4. The H3 proteins are oriented in cis so 
that the unfolded N-terminal tails protrude away from the nucleosome in the same direction (Luger, 
1997) (Figure 2.1B). One or both H3 tails (Voigt, 2012) can become trimethylated at lysine 27 by 
the enzyme enhancer of zeste (EZH) (Kuzmichev, 2002). Therefore, tandem PCDs in the 
multivalent protein Pc2TF might interact with two histone post translational modifications (PTMs) 
in a single nucleosome (Figure 2.1B) or single PTMs on adjacent nucleosomes.  
To quickly and efficiently identify a linker that would allow contact of each PCD with a 
H3K27me3 ligand, we used an in vitro expression and ELISA procedure to test four Pc2TF variants. 
Different lengths and physical characteristics were explored by using flexible glycine−serine linkers 
(Wriggers, 2005) and rigid α- helical (Merutka 1991; Yan, 2007) linkers. Glycine and serine, amino 
acids with small side chains, have been used in a wide range protein engineering applications to 
build linker peptides that have minimal interference with the function of tethered proteins. However, 
as was demonstrated by mutagenesis of a rigid linker in the bivalent protein BPTF, added flexibility 
can destabilize protein−histone interactions (Ruthenburg, 2011). Rigid linkers might perform better 
by stabilizing the distance between PCDs to support interactions with neighboring K27me3 moieties 
(Shewmake, 2008; Chen, 2013). The Pc2TF constructs included two tandem copies of the PCD 
separated by one of four linkers: flexible (GGGGS)4, long flexible (GGGGS)16, rigid (EAAAR)4, 
and long rigid (EAAAR)16. Based on a simplified layout of the interacting components (PCDs and 
a nucleosome carrying two H3K27me3 modifications; Figure 2.1B), we predicted that 20 amino 
acids would provide sufficient length for adjacent PCDs to bind simultaneously. The 80-amino-acid 
linkers were used to determine the impact of increased spacing between PCDs.  
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Figure 2.2. Comparison of Pc2TF variants that were expressed in a bacterial cell-free expression 
system. (A) Map of the expression vector and open reading frames (ORFs). Fusion-encoding ORFs 
were cloned in the pET28 vector at BamHI and XhoI. (B) Real-time detection of mCherry 
fluorescence was used to determine expression of recombinant protein in TXTL in a 96-well PCR 
plate in a Roche thermal cycler. Each replicate is an independent TXTL reaction in a single well (1 
replicate for PcΔTF and TXTL without DNA, 3 replicates for others). Replicates were pooled for 
ELISAs in panel C. Solid line = mean, shaded regions = SDM. (C) The bar chart shows mean signal 
from anti-mCherry-HRP signal at an absorbance of 450 nm (3 ELISA wells) from TXTL-expressed 
fusion proteins or plasmid-free “blank” TXTL captured by tethered trimethyl-K27 (K27me3), 
unmodified (K27), or modified nontarget (K27ac) histone H3 peptides. For each TXTL product, 
individual values are normalized to the unmodified H3 mean value within the set (error bars = SDM).  
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To expedite the prototyping stage, we used a cell-free expression system (Caschera, 
2014). Pc2TF variants and a control protein with no binding domain (PcΔTF) were expressed from 
a pET28 vector (Figure 2.2A) in TXTL solution. Real-time detection of mCherry fluorescence in a 
Roche thermal cycler confirmed expression of recombinant proteins. For ELISAs, biotinylated 
histone peptides were immobilized on a neutravidin-coated 96 well plate. HRP-conjugated anti-
mCherry was used for immunodetection of bound fusion proteins. Significantly higher HRP signal 
was detected compared to background (unmodified K27 and K27ac) for variants that contained the 
flexible (GGGGS)4, long flexible (GGGGS)16, and long rigid (EAAAR)16 linkers (Figure 2.2C). The 
implications of these results are discussed in depth in the Conclusions. Assuming that HRP signal 
is proportional to Pc-fusion molecules bound, the flexible (GGGGS)4 linker conferred the strongest 
avidity in this assay. Therefore, we used this variant in subsequent experiments to determine the 
impact of bivalency on the activity of synthetic, histone-binding effectors. 
 
Figure 2.3. A bivalent PCD fusion peptide shows enhanced avidity for H3K27me3 in microspot 
array experiments. (A) For high-yield expression, E. coli was transformed with pET28 plasmids 
encoding PcΔTF (negative control), PcTF (single PCD), and the Pc2TF containing the flexible linker 
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(GGGGS)4. Native polyacrylamide gel electrophoresis (PAGE) of overexpressed proteins purified 
from E. coli. (B) Test slides were spotted with histone H3 peptides (K27me3 or unmodified K27) as 
indicated in the grid for qualitative analysis. Pseudocolored images show mCherry signal after an 
application of 1.0 μM fusion protein to individual arrays. (C) New arrays were spotted with 10, 20, 
and 50 μM H3K27me3 for quantitative analysis. Fluorescence signal versus the concentration of 
fusion protein applied to the array was used to calculate the apparent dissociation constant (Kadpp, 
not applicable for PcΔTF). Each point in the graph is the mean signal from four spots in one 
application (error bars = SDM). The data displayed in the graph are from representative applications 
(out of four total) for 20 μM immobilized H3K27me3.  
2.2.2 Bivalency Strengthens the Avidity of the Pc-Fusion for H3K27me3.  
To compare known concentrations of Pc- fusion proteins in subsequent experiments, we 
overexpressed and purified recombinant proteins from E. coli. Denaturing polyacrylamide 
electrophoresis (PAGE) of lysates from isopropyl β-D-1-thiogalactopyranoside (IPTG)-treated and 
untreated E. coli confirmed inducible production of the proteins at roughly the expected sizes: 37, 
44, and 52 kDa for PcΔTF, PcTF, and Pc2TF, respectively (Figure 2.3A). Nickel-NTA column-
purified proteins were soluble in 1× phosphate buffered saline (PBS). The visible red hue under 
white light, which is typical of the mCherry protein, (Shen, 2017) indicated proper protein folding 
(Figure 2.3A).  
To determine impact of the additional PCD domain on PcTF avidity, we exposed tethered 
histone peptides to varying concentrations of soluble PcTF and Pc2TF. Liquid phase ligand 
(H3K27me3 peptide) binding assays (fluorescence polar- ization, FP) reported by other groups 
have determined affinities of N-terminal PCD motifs from the Drosophila Pc protein (residues 1−90, 
Kd = 5.0 ± 1 μM (Fischle, 2003)) and mammalian CBX8 protein (mouse residues 1−62, Kd = 165 
± 20 μM; (Bernstein, 2006) human residues 8−61, Kd > 500 μM (Kaustov, 2011)). The amino acid 
sequence of the PCD in our fusion proteins (human CBX8 residues 1−62) is identical to the mouse 
ortholog. To acquire data that is relevant to the full-length fusion proteins (295 to 445 residues) that 
we had previously tested as gene regulators in cancer cell lines (Nyer, 2017), we used a histone 
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peptide microspot array. We used a mathematical model to predict relative RFP signal levels after 
Pc-fusion binding and subsequent washing of the microarray. PcTF has a higher mCherry/PCD 
ratio than Pc2TF (1:1 versus 1:2). Therefore, PcTF should show higher relative RFP signal when 
all targets (H3K27me3 peptides) within a microspot are saturated by PCD binding (Figure S1). 
Assuming that bivalency supports an additive increase in avidity, a higher fraction of Pc2TF 
molecules should remain bound at the microspot during washing, resulting in higher total RFP 
signal. Results from a test array were consistent with this prediction (Figure 2.3B). We tested 
concentrations of the recombinant proteins over 2 orders of magnitude (0.2−20 μM) to determine 
the apparent dissociation constant (Kadpp) of each protein for 10, 20, and 50 μM tethered 
H3K27me3 ligand (Figure S2). We detected no interaction with unmodified histone H3 peptides 
and very little signal above background for the PcΔTF negative control. The Kadpp of monovalent 
PcTF was 5.14−8.95 μM for four independent trials (Figure 2.3C and S2). The micromolar Kadpp 
values are comparable to Kd values from the aforementioned FP experiments, although the wash 
steps in microspot assay may bias Kadpp toward the off kinetics of the binding process. We 
conclude that PCD retains its intrinsic affinity for H3K27me3 as an N-terminal motif within a fusion 
protein.  
Overall, analysis of the microspot array data suggest that at 10 and 20 μM of H3K27me3 
the Kadpp of Pc2TF is roughly 2- fold smaller than PcTF (Figure S2). Assuming that the second 
PCD fold (PCD2) maintains its intrinsic affinity, PCD2 should approximately double the overall 
association rate for Pc2TF since there is twice the chance of a PCD−H3K27me3 collision. Avidity 
is related to the inverse of the equilibrium constant, and the equilibrium constant is proportional to 
the ratio of association rate over dissociation rate. Thus, the effect we observed is most likely due 
to increasing the association rate or decreasing the dissociation rate, which would decrease the 
Kadpp value (compared to PcTF) roughly 2-fold.  
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2.2.3 Bivalent Pc2TF Shows Cooperative, On-Target Binding with Solid Phase Target Ligands. 
Next, we investigated the binding properties of the mono- and bivalent PCD proteins over 
a range of target ligand densities to approximate dynamic distributions of H3K27me3 that may 
occur in chromatin. We assumed that random distribution within each mixture would decrease the 
spacing between H3K27me3 targets as their concentration was increased. We applied dilutions of 
the target ligand (0−100% H3K27me3 mixed with unmodified H3K27, 1000 nM final concentration) 
to ELISA wells and exposed the immobilized ligands to the highest concentration of fusion proteins 
that produced minimal background signal in preliminary ELISA trials (0.1 μM). At 0−15% 
H3K27me3, HRP signal for PcTF or Pc2TF was not significantly greater than the negative control 
fusion protein (PcΔTF). In this range, the number of fixed H3K27me3 ligands may not have 
captured enough fusion proteins to yield detectable signal after washing. At 20−30% and higher, 
the HRP signal from the PcTF and Pc2TF wells increased with H3K27me3 concentration. 
 
  14 
Figure 2.4. Bivalent Pc2TF shows cooperative and on-target binding with H3K27me3 ligands. (A) 
The scatter plot shows mean HRP signal at an absorbance of 450 nm (one ELISA trial, means of 
four technical replicate wells, error bars = SDM) from wells in which 0.1 μM purified protein (Pc2TF, 
PcTF, or PcΔTF) was allowed to bind with different proportions of H3K27me3 biotinylated peptides 
(0−100%) mixed with unmodified H3 and tethered to neutravidin-coated surfaces. (B) Hill curves 
were fit to data for three ELISA trials (dots = technical replicate wells from all trials). (C) ELISA was 
used to detect interaction of 0.05 μM purified proteins with immobilized histone H3 peptides that 
were trimethylated at lysine 27, 4, or 9 or unmodified. The bar chart shows mean signal values from 
anti-mCherry-HRP at an absorbance of 450 nm (4 technical replicates, bars = SDM).	 
A Hill slope of 2.75 from the nonlinear regression (R2 = 0.90) for Pc2TF (Figure 2.4B) 
indicates that binding scales nonlinearly with the concentration of its ligand. It is difficult to fit a Hill 
curve to the data for PcTF (R2 = 0.64) because the increase in HRP signal is interrupted by a 
plateau at 30−80% H3K27me3. The cause of the plateau is unclear; however it is possible that the 
increase observed above 80% is due to the binding avidity between PcTF and H3K27me3 being 
exceeded at these concentrations. Overall, we can conclude from the ELISA data that Pc2TF 
binding is cooperative.  
To investigate ligand selectivity, 50 nM purified PcTF, Pc2TF, or PcΔTF was tested for 
interaction with histone peptides that were trimethylated at different lysine residues. PcTF and 
Pc2TF showed significant binding with H3K27me3 peptides compared to the control protein PcΔTF 
(Figure 2.4C). HRP signal from the H3K27me3 wells was significantly higher than what appears to 
be nonspecific binding with unmodified H3. This was not the case for off-target ligands H3K4me3 
and H3K9me3, suggesting that the Pc-fusions can discriminate between the different methyl marks. 
No significant increase in HRP signal in the off-target wells was observed for Pc2TF, suggesting 
that target preference was not lost as avidity was enhanced. One might expect cross-reactivity with 
H3K9me3 since this PTM appears within a similar motif (ARKS) as H3K27me3 (Fischle, 2003; 
  15 
Kaustov, 2011). Others have reported that in vitro, chromo- domain peptides from different 
orthologues (CBX1−8) have varying preferences for the two histone modifications (Bernstein, 2006; 
Kaustov, 2011; Vermeulen, 2010). CBX8, the PCD used for PcTF in our work, has shown weak 
affinity for H3K27me3 and none for H3K9me3, (Bernstein, 2006; Kaustov, 2011) which is consistent 
with our results.  
The results from the assays with purified proteins led us to ask what is the biological 
consequence of increased binding in living cells where the physical distribution of H3K27me3 is 
much different? In the cellular chromatin environment, H3K27me3 can occur in cis on the radial 
surface of a single nucleosome (Figure 2.1B), in trans where DNA bending brings the H3 tails of 
neighboring nucleosomes close together, or sparsely distributed across many nucleosomes. 
Furthermore, H3K27me3 marks in living cells are dynamic. The enzyme EZH1/2 adds methyl 
groups to H3K27, and the enzymes KDM6A (UTX) and KDM6B (JMJD3) remove these marks 
(Swigut, 2007). We set out to compare Pc2TF to PcTF in a cellular milieu.  
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Figure 2.5. Pc2TF stimulates expression at a polycomb-silenced reporter gene. (A) An engineered 
HEK293 cell line, Gal4-EED/luc, was used for doxycycline-mediated control of H3K27me3 and 
PRC-mediated silencing at a Tk-luciferase reporter. Expression is partially silenced prior to dox 
treatment, as demonstrated previously (Daer, 2017) and becomes fully repressed at 96 h. (B) 
Fusion constructs were cloned into the MV10 vector at XbaI. Fluorescence microscopy confirmed 
nuclear localization of the fusion proteins in transfected cells. The same samples were used for 
Western blots to confirm cellular expression of full-length proteins, RT-qPCR to measure mRNA 
levels (C), and flow cytometry to measure RFP signal (D). Changes in the expression states of Tk-
luciferase in 96-h dox-treated cells were determined by RT-qPCR (C) and luc activity assays (D) 
(circles = replicates, described in Methods). (E) Fusion proteins were expressed in cells treated 
with dox for 0, 48, or 96 h to determine the activity of the fusion activators at intermediate repressed 
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states (bars = mean values for 3 luciferase assays from one transfected sample, each scaled to 
mean PcΔTF luc/ cell; error bars = SDM).  
2.2.4 Bivalent Pc2TF Activates a Target Gene in a Partially Silenced State.  
Previously, we demonstrated that PcTF activated a reporter gene near ectopic H3K27me3 
in HEK293 cells (Haynes, 2011). Here, we determined the biological significance of PCD bivalency 
by comparing the gene-regulation activities of Pc2TF and PcTF at the same reporter. Doxycycline 
(dox)-mediated induction of Gal4-EED in HEK293 Gal4-EED/ luc cells leads to accumulation of 
H3K27me3 at and silencing of a chromosomally integrated Tk-luciferase transgene (Figure 2.5A) 
(Daer, 2017; Hansen, 2008). Tk-luciferase repression reaches steady state at 96 h, (Daer, 2017) 
and repression is maintained by epigenetic inheritance after loss of Gal4-EED (Hansen, 2008).  
We transfected dox-treated cells (96 h) with the PcΔTF negative control, PcTF, or Pc2TF 
cloned into a mammalian expression vector (Figure 2.5B). Fluorescence microscopy and Western 
blots confirmed nuclear localization and expression of full-length proteins. Using reverse 
transcription followed by quantitative PCR (RT-qPCR), we detected higher luciferase transcript 
levels in Pc2TF and PcTF-expressing cells compared to PcΔTF (Figure 2.5C). These results 
indicate that bivalent Pc2TF is a stronger activator than PcTF. Luciferase (luc) activity levels 
detected by an enzymatic assay (Figure 2.5D) and normalized to RFP signal-to-noise ratios from 
flow cytometry corroborated the RT-qPCR results; Pc2TF stimulated greater luc expression than 
PcTF. We did not detect significantly higher luc activity for PcTF-expressing cells versus the 
negative control in this trial (Figure 2.5D), but did so in additional experiments (Figure 2.5E).  
Expression of fusion regulators in cells that were treated with dox for 0, 48, and 96 h 
showed that Pc2TF had roughly twice the activity as PcTF (96 h) and that Pc2TF activated Tk- 
luciferase without prior dox-induced silencing (Figure 2.5E). The latter result can be explained by 
an intermediate, partially silenced level of Tk-luciferase expression (Daer, 2017) compared to fully 
active Tk-luciferase in a “Luc14” parental cell line that lacks the Gal4-EED gene, as previously 
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observed (Daer, 2017). H3K27me3 was detected via chromatin immunoprecipitation (ChIP) 
coupled with qPCR (ChIP-qPCR) near the luciferase promoter (Tk) in uninduced Gal4-EED/luc 
cells at significantly higher levels than in Luc14 cells. Dox treatment resulted in a further decrease 
in Tk-luciferase expression and a significant increase in H3K27me3 accumulation. In the 
experiments reported here, basal Tk- luciferase expression (Figure 2.5A) agrees with independent 
experiments from our prior study (0.02−0.07 luciferase activity per cell, au) (Daer, 2017). The 
uninduced state may have low levels of H3K27me3 at nucleosomes near the reporter gene in all 
cells or high levels of H3K27me3 at the reporter gene in a small proportion of cells in the population. 
In contrast to Pc2TF, monovalent PcTF only activated Tk-luciferase after silenced chromatin had 
been induced for 96 h. These results suggest that Pc2TF is more tolerant of low levels of 
H3K27me3 in cellular chromatin. 
 
2.3 Conclusions 
This report presents the first demonstration of modular, synthetic multivalency of a 
chromatin-derived histone-binding protein with gene-regulating activity. In our previous work, we 
have demonstrated the use of a monovalent synthetic effector to activate chromatin-silenced genes 
in live cells. Natural bivalent chromatin proteins that recognize two histone post- translational 
modifications at once suggest a broader design space for synthetic chromatin effectors. Our 
application of bivalency to design a synthetic fusion protein produced two important advances for 
engineering synthetic chromatin effectors. First, we determined that synthetic linkers allow tethered 
histone PTM-binding peptides to function within the context of a fusion protein in vitro and in live 
cells. Second, we have established that doubling the valency with tandem PCDs strengthens avidity 
and increases gene regulation activity by at least 2-fold.  
Here, we demonstrated that different synthetic linkers allow tethered histone PTM-binding 
peptides to bind in vitro to varying degrees. We observed weaker binding for the longer flexible 
linker (80 amino acids) compared to the shorter linker in our ELISA experiment. This result is likely 
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due to lower production of the long flexible linker variant in TXTL. Given that both variants showed 
binding above background, GGGGS- repeat number may not significantly affect bivalent PCD 
engagement with H3K27me3 in vitro. For the rigid linker- tethered PCDs, only the longer length (80 
amino acids) appeared to support binding. Assuming that this variant protein was properly folded, 
lack of binding over background for the shorter EAAAR-repeat variant could be caused by 
suboptimal rotation, that is, in trans instead of in cis, of the second PCD away from the 2-D binding 
surface in the ELISA well. This mechanism was demonstrated with mutated α-helical linkers in 
bivalent BPTF (Ruthenburg, 2011) and with tandem zinc finger DNA binding domains (Yan, 2007). 
In the context of cellular chromatin where looping and folding occurs, H3K27me3 would not 
necessarily be constrained to one face of the Pc2TF protein. Valuable insights and perhaps greater 
Pc2TF performance might be acquired by exploring additional linker variants in cells as well as in 
vitro. Such work is beyond the scope of the studies reported here, which accomplished a major 
step by identifying a functional bivalent synthetic effector protein that specifically interacts with its 
target H3K27me3.  
We have established that tandem PCDs strengthen avidity for H3K27me3 in a cooperative 
manner in vitro and increase gene regulation activity in live cells by at least 2-fold compared to a 
monovalent PCD. The wide distribution of multivalency within bromodomain family 
(Filippakopoulos, 2012) and other effector proteins (Ruthenburg, 2011) suggests that multivalent 
engagement has an important, evolutionarily conserved biological role. Multivalency appears to 
largely be represented by cell-cycle and gene-activating effectors. Relatively few multivalent 
proteins that recognize silencing marks have been studied in biophysical detail. Examples include 
the chromodomains of the Arabidopsis protein CMT3 (Lindroth, 2004) and the mammalian protein 
HP1β; (Hiragami-Hamada, 2016) as bivalent homodimers, these proteins show enhanced 
interaction with their respective ligands H3K9meK27me and H3K9me3. Pc2TF is novel in its 
composition of histone-binding motifs: adjacent, identical polycomb chromodomains within a single 
peptide. Therefore, its activity in vitro and in cells provides new insights into the recognition of 
histone marks by effector proteins.  
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In the context of cellular chromatin, Pc2TF appears to be active at the target gene prior to 
full repression (Figure 2.5E, 0 h dox), whereas detectable activity of monovalent PcTF required a 
prolonged period of induced repression at the target (Figure 2.5E, 96 h dox). Our previous ChIP 
mapping data (Daer, 2017) confirm that compared to the fully active and fully silenced states, 
intermediate levels of H3K27me3 appear at Tk-luciferase (on average) without the addition of 
doxycycline. It is likely that in the pretreated state, leaky Gal4-EED expression causes a few cells 
in the population have one or two H3K27me3 marks at a nucleosome near the Tk promoter. 
Stronger avidity, supported by the additional PCD module, may increase the likelihood of an 
activation event at the target in this small population of cells. This idea is consistent with the 
behavior of synthetic zinc finger-based DNA-binding regulators, where stronger affinity of the 
regulator for its DNA target is associated with stronger gene activation (Khalil, 2012). Similar 
behavior can also be observed for multivalent receptor-binding peptides, which bind with high 
avidity and specificity to a small number of receptor-positive cells (Rosca 2009).  
Further engineering efforts to achieve greater nonlinear enhancement of PcTF/Pc2TF may 
require changes within the PCD binding motif. The hydrophobic interaction between the 
methylammonium cage and the methyl-lysine moiety (Figure 2.1A) depends upon proper 
positioning of PCD residues that appear discontinuously in the primary sequence; this positioning 
requires specific intramolecular contacts of peptide residues within the PCD fold. Reverse 
engineering and de novo design of a new binding pocket through randomization of sequences 
would likely yield many nonfunctional proteins. K27-adjacent interactions that contribute to 
interactions with the histone tail (Fischle, 2003) could be leveraged to enhance affinity. However, 
increasing the stability by introducing additional hydrogen bonding could overwhelm the 
hydrophobic, K27me3-specific interaction and allow PCD to recognize unmodified tails or off- target 
modifications. Trade-offs between affinity and specificity pose formidable challenges to enhancing 
PCD affinity. Therefore, the most practical strategy for identifying alternative PCDs is to leverage 
H3K27me3-specific orthologues and paralogues from various species (Senthilkumar, 2009). It will 
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be important to determine cross-reactivity with different histone modifications since certain CBX 
PCD peptides have been shown to bind H3K9me3 (Bernstein, 2006).  
Multivalent engagement of combinatorial histone marks has recently become a key line of 
evidence to support the controversial histone code hypothesis. Rationally designed synthetic 
multivalency will advance this important area of research by exploring functions beyond the limits 
of pre- existing natural multivalent proteins. Furthermore, engineered chromatin effectors provide 
a practical tool to support artificial regulation of gene expression states through direct engagement 
with highly conserved components of chromatin, that is, histone tails and their modifications. 
Therapeutic synthetic gene regulators that leverage this mechanism could help circumvent the 
shortcomings of epigenetic inhibitors, which target chromatin enzymes that can gain drug-resistant 
mutations (Gibaja, 2016; Baker, 2015). In conclusion, our findings demonstrate that synthetic 
biology is a powerful tool for fundamental investigations of chromatin biology and epigenetic 
engineering.  
2.4 Methods 
2.4.1 Plasmid Constructs for TXTL and Bacterial Expression.  
Constructs (Figure 2.2A, Figure 2.3A) were assembled as BioBrick compatible fragments in vector 
V0120 (Phillips, 2006). Fragments were PCR- amplified with Phusion polymerase using primers 
1−6 (Table S1) and a protocol adapted from New England Biolabs Phusion High Fidelity DNA 
Polymerase (98 °C 0:45, [98 °C 0:10, 67 °C 0:20, 72 °C 0:45] × 25, final extension of 5:00), column 
purified (Qiagen PCR Cleanup Kit), and double-digested with BamHI and XhoI (New England 
BioLabs). BamHI/XhoI- digested inserts and 50−75 ng of BamHI/XhoI linearized pET28(+) vector 
were ligated at a 3:1 molar ratio in a 20 μL reaction as described in the New England BioLabs 
(NEB) protocol for T4 ligase (M0202). Five microliters of each ligation was incubated with 50 μL of 
Turbo competent DH5- alpha E. coli (NEB) on ice for 5 min, transferred to 45 °C for 45 s, then to 
ice for 5 min, and allowed to recover in 350 μL of SOC medium at 37 °C with shaking for 30 min. 
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Pelleted cells were resuspended in 50 μL of SOC, plated on LB agar (50 ug/ mL kanamycin), and 
grown at 37 °C overnight. Colony PCR was performed to identify positive ligation results using 
primers 6 and 7 (Table S1) and the GoTaq Promega protocol. Plasmids were cloned, extracted 
(Sigma GeneElute Plasmid Miniprep Kit), and Sanger sequenced for verification prior to protein 
expression in cell-free TXTL or in E. coli. Annotated sequences for all pET28 constructs are 
available online at Benchling- Hayneslab: Synthetic Chromatin Actuators 2.0 (https:// 
benchling.com/hayneslab/f_/rmSYkAAU-synthetic-chromatin- actuators-2-0).  
2.4.2 TXTL: Cell-free Expression.  
TXTL reactions were set up with the following conditions as previously described: (Caschera, 2014) 
9 μL of lysate, 10 nM final template vector, 0.5 nM σ70-T7 RNA pol vector to a total of 12 μL. A 
Roche Lightcycler 480 was used to detect mCherry fluorescence with the following protocol: 29 °C 
for 10 min, bring to 30 °C for 1 s, scan 533−610 nm, repeat 96 times (total 16 h).  
2.4.3 E. coli Expression and Purification of Proteins.  
All selection media contained 50 μg/mL kanamycin. PcΔTF, PcTF, and Pc2TF in pET28 were 
transformed into Rosetta 2pLys DE3 cells and plated on LB agar and grown at 37 °C overnight. 
The next day, a single colony from each was used to inoculate 50 mL of LB and grown overnight 
at 37 °C at 300 rpm. The next day, 1 L of LB in a baffled Erlenmeyer flask was inoculated to an 
OD600 of 0.1. The cultures were grown to an OD600 = 0.6, induced with IPTG (1 mM final 
concentration), and allowed to express PcΔTF and PcTF at 37 °C for 5 h with shaking (220 rpm). 
Pc2TF expression was carried out overnight at room temperature with shaking (220 rpm) to aid 
solubility of the protein. Cell disruption and protein purification are described in detail in Supporting 
Information and Methods. Purification of recombinant protein from E. coli is described in Supporting 
Information (Methods).  
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2.4.4 Enzyme-Linked Immunosorbent Assays (ELISAs).  
All steps were carried out at room temperature except specifically noted, and all incubations and 
washes were agitated at 800 rpm on an Eppendorf Thermomixer R. Clear bottom plates (Greiner 
bio-one #655101) were coated in 50 μL of 20 ng/ μL neutravidin in PBS pH 8.0 overnight at 4 °C. 
The plates were washed the next day 3× with 200 μL of 0.2% PBS-Tween (PBST) with 5 min of 
shaking at 800 rpm between washes. The plate was blocked for 30 min at 800 rpm at room 
temperature with 200 μL of 5% BSA in 0.2% PBST followed by 3× washes microliters of 1 μM 
biotinylated peptides (Anaspec, H3 (21− 44), H3K4me3 (1−21), H3K9me3 (1−21), H3K27me3 (21− 
44), or H3K27Ac (21−43)) in 0.2% PBST) were incubated at room temperature for 1 h at 800 rpm, 
followed by 3× washes of 200 μL of 0.2% PBST for 5 min at 800 rpm. The plate was blocked with 
200 μL of 5% skim milk in 0.2% PBST (room temperature, 800 rpm, 30 min). TxTL, 1.5 μL (Figure 
2.2), or 50 μL of 0.1 μM (Figure 2.3A) or 0.05 nM (Figure 2.3C) purified proteins in 50 μL of 5% 
skim milk in PBST were incubated in each well for 1 h (room temperature, 800 rpm). The wells 
were washed 3× with 200 μL of 5% skim milk in PBST with 5 min of 800 rpm shaking. After adding 
100 μL of 1:3000 chicken polyclonal anti-mCherry (Novus Biologicals #NBP2−25158) in 5% nonfat 
milk in 0.2% PBST, wells were incubated for 1 h, followed by 3× of 200 μL of 5% skim milk in 0.2% 
PBST for 5 min each (room temperature, 800 rpm). After addition of 100 μL of 1:3000 rabbit anti-
chicken−HRP (RCYHRP Genetel 0.5 mg/mL) in 5% skim milk in 0.2% PBST wells were incubated 
for 30 min (room temperature, 800 rpm). The plate was washed 5× with 200 μL of 0.2% PBST for 
3 min each at 800 rpm. The plate was incubated with 100 μL of 1-step Ultra TMB-ELISA (Thermo-
Fisher #34029) for 15 min while protected from light. Reactions were stopped with 100 μL of 2.0 M 
sulfuric acid, incubated for 2 min, and read at 450 nm. Each plate contained four technical replicates 
per H3K27me3 concentration per fusion protein. Two ELISA plates (trials) were run for each of two 
purified protein samples per construct. One trial failed to show significant signal over background 
(for all recombinant proteins) and was omitted from the final analysis. In Figure 2.4 “anti-mCherry-
HRP (A450)” = HRP signal − mean HRP signal for 0% H3K27me3. The Microsoft Excel Solver tool 
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was used to fit the Hill equation, data by minimizing the sum of the squared errors between the 
data by minimizing the sum of the squared errors between the equation and data (varying Kapp  
d 
− (SSreg/SStot), where total sum of squares SStot = ∑i(yi − y)̅ 
2 and regression sum of squares 
SSreg = ∑i( f i − y)̅ 
2. R2 was calculated as 
single population of transfected cells. “Luc × cell−1 (au)” = [Sample Luciferase signal] − 1× PBS 
blank signal/[cell count × (100 μL/20 μL)]. For fusion protein-expressing cells, normalization was 
performed by dividing Luc × cell−1 by the RFP median signal/noise value (from flow cytometry).  
 2.4.5 Peptide Microspot Arrays.  
APTES functionalized glass slides were coated with 200 μL of 1:1 (v/v) 40 mg/mL BS3 cross-linking 
solution and 1 mg/mL neutravidin with a cover slide (Thermo Scientific, #651-2-5251) and 
incubated over- night at 4 °C. The next day, the cover slide was removed, and the slide was rinsed 
3× with 0.2% PBST for 5 min each. Slides were deactivated by incubation with Na2CO3/NaHCO3 
buffer, pH 9.4, for 30 min. The slides were quickly rinsed with ddH2O and centrifuged to dry at 1200 
rpm for 2 min. Slides were printed with biotinylated peptides (Anaspec) at concentrations of 10, 20, 
or 50 μM in 20% glycerol and PBS with a pin-printer (spot to spot distance = 600 μm) and incubated 
at room temperature for 1 h. The slide was rinsed with ddH2O as described above and blocked 
with superblock for 1 h at room temperature. Proteins were diluted in superblock and incubated on 
the slide for 1 h at room temperature. The slides were rinsed with 0.2% PBST for 3 min each 
followed by quick rinsing with ddH2O 3× and centrifuged dry (as described). Red fluorescent protein 
(mCherry) signal was detected at 50% gain and 50% intensity on a PowerScanner at 635 and 535 
nm, 10 μm resolution. Slides were also scanned at 75%−75% and 100%− 100% to obtain a suitable 
signal-to-noise ratio. Arraypro software was used to quantify the median intensity values for each 
spot and background levels. Graphpad Prism software was to fit the binding saturation nonlinear 
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regession equation, y = BmaxX/Kappd +X’, to the data, where Bmax is the highestbinding value and X 
is the concentration of protein. 
2.4.6 Plasmid Constructs for Mammalian Expression.  
MV10 was constructed from pcDNA3.1(+) (Invitrogen) with the following modifications. The CMV 
promoter was removed via SpeI digestion and T4 ligase recircularization. A dsDNA fragment that 
encodes Kozak (ribosome binding site), XbaI, a nuclear localization sequence, 6× histidine, and a 
stop codon (5′-cccgccgccaccatggagtctagacccaagaaaaagcgcaaggtacaccatcaccaccatcacgc-
gtaaagctgag) with SpeI overhangs at both ends (ctag/t) was inserted at XbaI. CMV (SpeI/XbaI 
fragment) was reintroduced upstream of Kozak at SpeI. Proper orientation of inserts was confirmed 
by Sanger sequencing. Constructs PcTF and Pc2TF (Figure 2.5B) were PCR-amplified (Phusion) 
with primers 9 and 10 (Table S1), double-digested with XbaI and SpeI, and column-purified (Qiagen 
PCR Purification, 28104). Construct PcΔTF (Figure 2.5B) was double digested with XbaI and SpeI 
(Thermo Fisher FastDigest) and isolated by electrophoresis and gel purification. XbaI/SpeI 
fragments and 25 ng of XbaI-linearized, dephosphorylated MV10 vector were ligated at a 2:1 molar 
ratio in a 10 μL reaction as described in the Roche protocol for Rapid DNA Ligation (11635379001 
Roche), using 1.0 μL of NEB T4 ligase instead of the supplied enzyme. All 10 μL of each ligation 
was incubated with 50 μL of Turbo competent DH5-alpha E. coli (New England Biolabs) on ice for 
5 min, transferred to 45 °C for 45 s, then to ice for 5 min. Cells were plated directly on prewarmed 
LB agar (100 μg/ mL ampicillin) without recovery and grown at 37 °C overnight. Plasmid DNA was 
prepared (Sigma GeneElute Plasmid Miniprep Kit) from 5 mL cultures inoculated with single 
colonies. Forward orientation of each insert was determined by XbaI and PstI double-digestion of 
prepped plasmids and Sanger sequencing. Annotated sequences for all MV10 constructs are 
available online at Benchling-Hayneslab: Synthetic Chromatin Actuators 2.0 
(https://benchling.com/hayneslab/f_/ rmSYkAAU-synthetic-chromatin-actuators-2-0).  
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2.4.7 Cell Culture and Transfection.  
 
HEK293 Gal4-EED/luc cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% tetracycline-free fetal bovine serum and 1% penicillin and streptomycin at 
37 °C in a humidified CO2 incubator. Silencing of the reporter gene (Tk- luciferase) was induced 
by supplementing the media with 1 μg/ mL of dox for 48 or 96 h. For wash-out of doxycycline (to 
allow depletion of Gal4-EED), growth medium was removed and replaced with dox-minus medium 
supplemented with 0.5 μg/ mL puromycin to select for the transgenic anti-Gal4-EED shRNA, 
(Hansen, 2008) and grown for 5 days. Prior to transfection, dox treated or untreated cells were 
plated in 12-well culture dishes at 40% confluency (∼1.0 × 105 cells per well) in 2 mL of pen/ strep-
free growth medium. Transient transfections were carried out by adding 100 μL of 
DNA/Lipofectamine complexes to each well: 1 μg pDNA or ddH2O for mock transfections (10 μL), 
3 μL of Lipofectamine LTX (Invitrogen), 87 μL of Opti- MEM. Forty-eight hours after transfection, 
cellular mCherry (580/610 excitation/emission) was imaged in culture dishes on a Nikon Eclipse Ti 
wide field inverted fluorescent microscope (MEA53100) at 200× magnification (eyepiece = 10×; 
objective = CFI S Plan Fluor ELWD 20×, numerical aperture = 0.45), 25 °C, without oil immersion, 
and with either phase contrast or an mCherry filter set (TE2000 cube, excitation FF01-562/40-25, 
emission FF01-641/75-25). Images from each channel were acquired with a digital monochrome 
camera (Coolsnap ES2 12 bit, 20 MHz) and overlaid using NIS-Elements software. For downstream 
assays (RT-qPCR, Western blots, and flow cytometry), the growth medium was removed, 
semiadherent cells were gently collected with 1× PBS washes, pelleted (200 g, room temperature, 
5 min), and resuspended in 1× PBS. Six replicate samples (wells) were pooled for assays in Figure 
2.5B,C,D.  
2.4.8 RT-qPCR.  
Preparation of total RNA, cDNA synthesis, and qPCR were performed as previously described 
(Nyer, 2017) using ∼1.0 × 106 HEK293 Gal4-EED/luc cells that were pelleted (500 g, room 
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temperature, 5 min) and lysed with 500 μL of TRIzol (Thermo Fisher #15596026). DNA/LNA oligos 
for qPCR were as follows: mCherry, forward 5′-cctgaagggcgagatcaag, reverse 5′-
ttgacctcagcgtcgtagtg, LNA probe #41 (Millipore Sigma #04688007001); luciferase, forward 5′-
caggtctt- cccgacgatg, reverse 5′-gtctttccgtgctccaaaac, LNA probe #70 (Millipore Sigma 
#04688937001); GAPDH (reference), Roche human G6PD assay (Millipore Sigma #5046246001). 
Mean Crossing point (Cp), the first peak of d2y/dx2 (fluorescence over cycle number), was 
calculated by the Roche LightCycler 480 software for three replicate wells per unique reaction. For 
each biological replicate (one transfection per fusion protein) two replicate cDNA synthesis 
reactions (from one RNA prep) were completed. Expression level was calculated as ΔCp = 
2[Cpreference − Cp]. “mRNA level log2(FC)” = log2(ΔCp- (transfected cells)/ΔCp(mock)).  
2.4.9 Western Blots.  
Total protein was prepared from roughly 250 000 cells. Sample preparation, polyacrylamide gel 
electro-phoresis (PAGE), and membrane blotting are described in detail in Supporting Information. 
Immunostaining was carried out with the following: blocking buffer, 5% nonfat dry milk in 1× PBST 
(1× PBS, 0.1% Tween-20); primary 1, chicken polyclonal anti-mCherry, 1:2000 (Novus Biologicals 
#NBP2- 25158); secondary 1, HRP-conjugated rabbit anti-chicken, 1:2000 (Millipore Sigma 
#AP162P); primary 2, anti-histone H3, 1:1000 (Abcam #ab1791); secondary 2, HRP-conjugated 
goat anti-rabbit, 1:2000 (Cell Signalling Technology #7074). Immunostaining was performed at 4 
°C overnight (primary) or at room temperature for 1 h (secondary) with nutation in a Parafilm pouch 
(Quadri, 2015). Immunostained blots were washed 4 × 10 min in 1× PBST, with orbital shaking at 
room temperature. HRP signal was detected using the SuperSignal West Femto substrate kit 
(Thermo Fisher #34095) and a PXi4 imager (Syngene) with GeneSys software.  
2.4.10 Imaging and Flow Cytometry.  
Cells were passed through a 35 μm nylon strainer (EMS #64750-25). Red fluorescent signal from 
mCherry was detected on a BD Accuri C6 flow cytometer (675 nm LP filter) using CFlow Plus 
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software. Data were further analyzed using FlowJo 10.0. One run (∼10 000 live cells, gated by 
forward and side scatter) was completed per sample. “RFP median signal/noise (S/N)” = {median 
RFP signal from live RFP-positive cells}/{median RFP noise from live untransfected cells}.  
2.4.11 Luciferase Assays.  	
Cell counts (per 100 μL) were determined by flow cytometry (BD Accuri C6). Cells (100 μL) or 1× 
PBS (blank) were incubated with 100 μL of complete luciferase assay reagent as described in the 
protocol for the Biotium Firefly Luciferase Assay Kit (89138-960) and in previous work (Daer, 2017) 
in Corning and Costar 96-well Cell Culture Plates, opaque, white (Corning 3789A). 
Chemiluminescence was detected using a Synergy H1Multi-Mode Reader (Biotek). Replicates 
included three samples (100 μL each) taken from a single population of transfected cells. “Luc × 
cell−1 (au)” = [Sample Luciferase signal] − 1× PBS blank signal/[cell count × (100 μL/20 μL)]. For 
fusion protein-expressing cells, normalization was performed by dividing Luc × cell−1 by the RFP 
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CHAPTER 3 




Figure 3.1 PcTF fusion protein model. (A) The EZH1/2 subunit of PRC2 catalyzing the addition of 
the trimethyl group to H3K27. (B) The natural Polycom-mediated silencing with CBX responsible 
for the binding of the H3K27me3 silencing epigenetic mark. (C) PcTF is made up of amino acids 1-
62 of the CBX8 protein from PRC1 and is linked to VP64 and targets H3K27me3 and reactivates 
silenced genes. 
 
It is often the case that an individual who has been diagnosed with cancer has been living 
some time without knowledge of its existence. Many cancers arise from epigenetically silenced 
tumor suppressor genes (Esteller, 2007; Baylin 2005; Herman 2003) which is brought on my 
hypermethylation of the DNA or as described in chapter 1, the methylation of histone tails. It is 
  30 
important to study the impact in which time under silencing has on a genes ability to be reactivated. 
Here, we demonstrate that by targeting these epigenetic silencing marks the length of time in which 
a gene is silenced becomes less important after 96 hours. Our assays used a transgenic cell line 
with a drug-inducible switch to control the expression of the reporter gene by changing the 
chromatin state at a single genomic locus also described in chapter 2. Also, in these experiments 
a we used a synthetic transcriptional activator named polycomb-based transcription factor (PcTF), 
this has been previously shown to recognize H3K27me3 and reactivate a silenced locus (Haynes 
2011).  
PcTF is a reengineered PRC1 utilizing its Polycomb chromodomain (PCD) attached to the 
transcription factor VP64. PcTF includes the first 62 amino acids from human CBX8 which 
preferentially binds to H3K27me3 (Fig 3.1) (Bernstein E 2006). This activator and its derivatives 
were chosen because of their ability to target the silenced epigenetic mark and our ability to control 
the addition of the H3K27me3 mark in the cell line HEK293 Gal4-EED (Hansen 2008).  
3.2 Results and Discussion 
 
Figure 3.2 Epigenetic silencing time course and reactivation by synthetic transcription factors. (A) 
Average differences in luc/cell of unsilenced and activator transfected cells. (B) Average luc/cell 
differences between silenced cells. Transfected cells were silenced with doxycycline for 0, 2, 4, 6, 
or 8 days followed by a PBS washout and transfection with DTF, PcTF, Pc2TF, Gal4TF, or empty 
liposome. Dox silenced cells with no transcriptional activator are shown in light grey. Dox silenced 
cells with PcTF derivatives are shown in red and a scaled to mean DTF luc/ cell. Silenced cells 
A B 
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transfected with the Gal4TF activator are shown in dark grey. (bars = mean values for 3 luciferase 
assays from one transfected sample, each scaled to mean DTF luc/ cell; error bars = SDM) 
 
Here we used a modeling silencing system developed by Hansen et al. that allows for the 
control of chromatin at a single locus with a stably integrated transgenic reporter, Tk-luciferase 
(Hansen, 2008). We can directly measure the amount of silencing and gene activation using a 
luciferase assay in conjunction with measuring RFP by flow cytometry. We have previously 
demonstrated that PcTF and Pc2TF are able to activate luciferase near the controlled ectopic 
H3K27me3 (Tekel S 2017, Haynes 2017, Hansen 2008). The induction of Gal4-EED in HEK293 
Gal4-EED/luc is mediated by the addition of doxycycline (dox) which leads to the accumulation of 
the H3K27me3 and the silencing of the integrated TK-luciferase transgene (Figure 3.3)(Hansen 
2008). 
 
Figure 3.3 Extended dox-mediated silencing and reactivation workflow. (A) Model for dox mediated 
silencing in HEK293 Gal4-EED/luc cell lines. (B)  Table showing the workflow for the dox induction 
timeline and washout.  (C) Plasmids used, plate setup, and fluorescent microscopy image from 
transfected cells. 
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HEK293 Gal4-EED/luc cells were grown in dox treated media for 0, 2, 4, 6, or 8 days 
followed by a washout at the end of day eight for all samples as shown in Figure 3.3B. We 
transfected dox-treated cells five days after washout, to allow residual Gal4-EED to be reduced, 
with the DTF negative control, PcTF, Pc2TF, or Gal4TF as positive control, cloned into a 
mammalian expression vector (Figure 3.3C). Fluorescence microscopy was used to verify the 
presence and localization of the transcriptional activators (Figure 3.3C). Using the Biotium Firefly 
Luciferase Assay Kit (89138-960) and running flow cytometry we detected that Gal4TF showed 
activation at all time points and regardless of silencing duration, this is to be expected because it 
is directly targeted to this region by the upstream 5xGal4 region (Figure 3.2A). In unsilenced cells 
transfected with DTF, PcTF, and Pc2TF activation of luciferase was not detected, this was to be 
expected due to the absence of the H3K27me3 (Figure3.2 A). In figure 5 B we have two sets of 
negative controls, cells silenced between two and eight days transfected with an empty liposome 
is shown in grey and indicates no activation, the second negative control is the DTF which also had 
no significant activation of luciferase. Cells silenced and transfected with PcTF Showed a delay of 
reactivation at the two-day timepoint but doubled the luciferase production per cell when being 
silenced for four days and up to eight (Figure 3.2B). Cells transfected with Pc2TF showed stronger 
activation at all timepoints however did show a drop off in luc/cell at eight days from 0.15 to 0.10 
luc/cell (Figure 3.2B). 
3.3 Conclusions 
This chapter presents a limited demonstration of PcTF and Pc2TF’s ability to reactivate 
after longer term silencing and also its limitations at reactivating genes that have not yet 
accumulated the epigenetic silencing mark. In previous work we have shown that both 
transcriptional activators have the ability to reactive chromatin-silenced genes up to 96 hours or 4 
days of silencing, but it has not been studied if extending this time inhibits this reactivation ability 
(Tekel 20018, Haynes 2011). This data further supports that the PcTF’s target and require the 
epigenetic silencing mark H3K27me3 and supports that utilizing these epigenetic marks can help 
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avoid any inherited resistances the are known to effect drug resistances in cancer (Brown 2014; 
Easwaran, 2014).  
3.4 Methods 
3.4.1 Cell Culture and Transfections 
HEK293 Gal4-EED/luc cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% tetracycline-free fetal bovine serum and 1% penicillin and streptomycin at 
37 °C in a humidified CO2 incubator. Silencing of the reporter gene (Tk- luciferase) was induced 
by supplementing the media with 1 μg/ mL of dox for 0, 48, 96, 144, or 196 h. For wash-out of 
doxycycline (to allow depletion of Gal4-EED), growth medium was removed and replaced with dox-
minus medium supplemented with 0.5 μg/ mL puromycin to select for the transgenic anti-Gal4-EED 
shRNA, (Hansen, 2008) and grown for 5 days. Prior to transfection, dox treated or untreated cells 
were plated in 12-well culture dishes at 40% confluency (∼1.0 × 105 cells per well) in 2 mL of pen/ 
strep-free growth medium. Transient transfections were carried out by adding 100 μL of 
DNA/Lipofectamine complexes to each well: 1 μg pDNA or ddH2O for mock transfections (10 μL), 
3 μL of Lipofectamine LTX (Invitrogen), 87 μL of Opti- MEM. Forty-eight hours after transfection, 
cellular mCherry (580/610 excitation/emission) was imaged in culture dishes on a Nikon Eclipse Ti 
wide field inverted fluorescent microscope (MEA53100) at 200× magnification (eyepiece = 10×; 
objective = CFI S Plan Fluor ELWD 20×, numerical aperture = 0.45), 25 °C, without oil immersion, 
and with either phase contrast or an mCherry filter set (TE2000 cube, excitation FF01-562/40-25, 
emission FF01-641/75-25). Images from each channel were acquired with a digital monochrome 
camera (Coolsnap ES2 12 bit, 20 MHz) and overlaid using NIS-Elements software. For downstream 
assay (flow cytometry), the growth medium was removed, semiadherent cells were gently collected 
with 1× PBS washes, pelleted (200 g, room temperature, 5 min), and resuspended in 1× PBS. Six 
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3.4.2 Imaging and Flow Cytometry.  
Cells were passed through a 35 μm nylon strainer (EMS #64750-25). Red fluorescent signal from 
mCherry was detected on a BD Accuri C6 flow cytometer (675 nm LP filter) using CFlow Plus 
software. Data were further analyzed using FlowJo 10.0. One run (∼10 000 live cells, gated by 
forward and side scatter) was completed per sample. “RFP median signal/noise (S/N)” = {median 
RFP signal from live RFP-positive cells}/{median RFP noise from live untransfected cells}.  
3.4.3 Luciferase Assays.  	
Cell counts (per 100 μL) were determined by flow cytometry (BD Accuri C6). Cells (100 μL) or 1× 
PBS (blank) were incubated with 100 μL of complete luciferase assay reagent as described in the 
protocol for the Biotium Firefly Luciferase Assay Kit (89138-960) and in previous work (Daer, 2017) 
in Corning and Costar 96-well Cell Culture Plates, opaque, white (Corning 3789A). 
Chemiluminescence was detected using a Synergy H1Multi-Mode Reader (Biotek). Replicates 
included three samples (100 μL each) taken from a single population of transfected cells. “Luc × 
cell−1 (au)” = [Sample Luciferase signal] − 1× PBS blank signal/[cell count × (100 μL/20 μL)]. For 
fusion protein-expressing cells, normalization was performed by dividing Luc × cell−1 by the RFP 
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CHAPTER 4 
CONCLUSIONS AND FUTURE RESEARCH 
(AS REQUIRED BY PREVIOUSLY PUBLISHED WORK DISCUS MY CONLUSIONS AND 
THOUGHT PROCESS FO FUTURE RESEARCH) 
4.1 Introduction 
In this chapter I will discuss the conclusion I have made regarding my contributions from the 
published article in Chapter 2 of this document. I will also discuss the projects I started shortly after 
completing my work with the in-cell data from the Tekel et. al paper. Luciferase assays produce an 
average expression level value, and information about variation between single cells is lost. 
Furthermore, output signal is heavily influenced by the quality of the D-luciferin substrate (which 
varies from lot to lot). We attempted to measure single cell luciferase protein levels with 
immunocytochemistry (ICC). In order to develop a simple assay that did not require antibody 
staining to detect silencing and reactivation of the PRC-silenced locus, we attempted to replace 
TK-luciferase with a cyan fluorescent protein (CFP). This would allow us to utilize flow cytometry to 
measure both the synthetic transcriptional activator and the reporter at the same time to avoid 
having to run two different assays to measure activation abilities. In another project we built a stably 
integrated cell line that has a dox inducible system that activates PcTF in response to dox, this was 
built in an MCF7 breast cancer cell line (Olney, 2018).  
4.2 Conclusion: Tandem histone-binding domains enhance the activity of a synthetic chromatin 
effector 
Based on the evidence from our paper the usefulness of synthetic histone-binding proteins with 
the ability to control gene activation is a valuable tool. By modifying natural proteins and changing 
their function like that of using the epigenetic binding mark from PRC1 and changing it in a way 
that allows it to remain a binding domain but by attaching an activator such as VP64 to change the 
molecule into an activator can change the way drugs are made. If a cancer such as cutaneous 
melanomas with a BRAF V600E mutation where the gene is being over expressed, we could build 
a synthetic protein that binds to a H3K4me3 and causes silencing or a reduction in expression 
could be therapeutic (Sandstorm 2014; Platz 2008). 
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In chapter 3 I wanted to determine if the age of the epigenetic silencing mark hinders or inhibits the 
ability of our multivalent or monovalent PcTF’s to reactivate and I decided to do an extended time 
course of dox-mediated silencing. There were several more experiments to be done to have a 
sufficient data to support that regardless of the age of silencing that our synthetic activators have 
the potential to “re-awaken” these silenced genes. Below I will describe other projects that were 
started to expedite testing of our chromatin effectors and also to add another level of complexity by 
moving from 2D models to 3D. 
4.3 Future research 
4.3.1 Measurement of single cell luciferase protein levels with ICC 
This experiment utilized ICC to collect single cell data on luciferase activity. This allowed 
for the use of both fluorescence microscopy as well as flow cytometry to collect data at the single 
cell levels and increase the ability to measure reactivation on a per cell basis. Below we present 
data from the cells grown and fixed to a coverslip and its associated fluorescent intensities. 
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Figure 4.1 Luciferase staining and quantification in situ. HEK293 Gal4-EED/luc cells were fixed to 
glass coverslips and fluorescently labeled using 𝛼-luc with a green fluorescent protein (GFP). (A) 
Shows cells treated with ten-fold dilution of dox and stained with 𝛼-luc and GFP along with a DAPI 
stain to identify the nucleus. (B) Bar chart comparing the mean intensity from the fluorescent 
microscopy images from Figure 4.1A with the grey bar being the negative control and the green 
outlined bar represents the positive control Luc14 cells. 
 Here we fixed HEK293 Gal4-EED/luc and HEK293-Luc14 cells to collagen coated 
coverslips and stained them with an 𝛼-luc and GFP in order to measure the mean intensity from 
several images. In Figure 4.1A treated cell lines are shown using fluorescent microscopy showing 
GFP differences across a serial dilution of dox. The same cells are also stained with DAPI to allow 
individual cells to be seen. In Figure 4.1B the mean intensities from each of the treated samples is 
represented as a bar graph. The green outlined bars represent the mean intensities of Luc14 and 
show a wider range of intensities when compared to those of the dox treated Gal4-EED/luc 
samples. Luc14 cells showed a range of 100-165 with a mean of 125 while the Gal4-EED/luc cells 
showed a narrower range from 105-125 with the mean at 120 correlated with a higher dox 
concentration. However, at 1.0E*10-3 we see a wider distribution similar to the Luc14 cell line. In 
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Figure 4.2 Immunocytochemistry: Luciferase stained dox treated cells followed by flow cytometry.  
 We also carried out an ICC assay, where cells were permeabilized and stained with 𝛼-luc, 
then analyzed by flow cytometry. In Figure 4.2 the mean GFP signal was measured from HEK293 
Gal4-EED/luc cells treat with a 10-fold dilution of dox and the parental cell line Luc14. Here we see 
a similar trend where the cells treated 1.0E *10-3 of dox show a similar signal to the parent cell line. 
We also see a similar trend of the Mean GFP signal decreasing as the concentration of dox is 
increased. This is similar to the data represented in Figure 4.1. We also see a higher mean intensity 
with the Gal4-EED/luc when compared to the Luc14 when using flow cytometry. The inconsistency 
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4.3.2 Luciferase replacement with CFP to enable single-cell studies of reactivation via PcTF 
 
Figure 4.3 CFP replacement of luciferase transgenic cell line colony selection. (A) Illustration of TK-
Luciferase replacement with HPK-AmCyan. (B) Model of the silence inducible HEK293 Gal4-
EED/CFP cell line and the silencing mechanism. (C) Single colony selection of CFP positive cells 
and their repossess to dox-mediated silencing. (D) Histogram of selected colony 3.1.7 comparing 
the cells under non-silenced and silenced conditions. (E) The same selected 3.1.7 colony grown in 
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medium without dox for 30 days and silence induced cells grown for 90 days and measuring the 
number of CFP-positive cells after each passage. 
 In this preliminary experiment we built a cell line that would replace the luciferase gene 
from Hansen et al. 2008 model cell line with CFP (Figure 4.3A and B). The variability of luciferase 
and the inconsistent measurements were not ideal. The replacement of TK-luciferase was carried 
out using Cas9/gRNA targeting the luciferase gene and causing a break in the DNA, HPK-AmCyan 
are flanked by homology arms (HA) HA1 and HA2 which match the 5xGal4 and polyA regions 
respectively. This would result in the HPK-CFP model in Figure 4.3B. This would allow for single 
cell reactivation to be measured. 
With a dox-mediated silencing of CFP we could utilize flowcytometry to measure both the 
reporter CFP and the mCherry from our synthetic protein and be able to utilize the one test to 
calculate the reactivation abilities of future proteins. In Figure 4.3C we showed that colony 3.1.7 
had the greatest reduction in CFP after the addition of dox to the growth medium, the selection for 
the most responsive CFP would show us which colony had the CFP in the correct position. In Figure 
4.3D we show the gating and the mean peak shift of the CFP fluorescence which is also plotted in 
Figure 4.3C. In Figure 4.3E we compared the silenced induced 3.1.7 colony to an non-induced 
3.1.7 colony over several months tracking the amount of CFP fluorescence reduction, the histogram 
also shows the colonies shifting from expression of CFP to none. This was one of the further 
expansions on the Tekel et al. paper. 
 Conclusions: Here we replaced the TK-luciferase transgene with an HPK-CFP transgene 
which appears to be less controllable than the former which is highlighted inFigure 4.3C. There 
could be a few reasons for the slow reduction in CFP due to promoter strength or protein stability 
(turnover). To test if the remainder of CFP expressing cells happen to be silence and CFP is 
remaining stable within the cell line it is possible to run RT-qPCR to measure the mRNA expression 
while also using a western blot to measure the CFP presence in cells treated with dox. However, if 
the presence of mRNA for CFP is present then the difference could be the HPK promoter. The use 
of the HPK could inhibit the state of the surrounding chromatin from being condensed and therefore 
silence CFP. The new transgenic reporter was added to the same region of the genome and should 
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not have a vital impact on the ability to silence the region. Making the cell line again with a TK-CFP 
could provide insight on the importance for these promoters regarding the ability of silencing 
complexes such as PcG to compact chromatin. 
 
4.3.3 Cancer spheroid growth assay to study the impact of PcTF on phenotype 
               
 
Figure 4.4 (A) Spheroid image overlay phase, (red) mCherry from the PcTF fusion being expressed, 
(green) part of the SBtet-GP fusion which allowed for selection of cell line. (B) Chart comparing 
untreated and dox treated transgenic cell lines containing either PcTF or PcDTF and the mean 
spheroid size overtime. (C) Sfil-flanked PcTF or PcDTF constructs were cloned into the pSBtet-GP 
expression vector which results in the replacement of luciferase (Olney 2018). (D) Selection tool 
images to show how data was collected (spheroids from day 9). 
  42 
 Here, the lab built two inducible cell lines that would allow for the induction of either PcTF 
or a negative, PcDTF, by a dox-mediated system in the breast cancer cell line MCF7. Expression 
of mCherry indicates that the PcTF proteins are being expressed and can be visualized using 
fluorescence microscopy (Figure 4.4A). In this experiment we tracked the growth rates of both PcTF 
and PcDTF under both dox-mediated expression and under normal growth conditions (absence of 
dox) (Figure 4.4B). The cells were grown on a plate shaker in a low adhesion 6-well plate that 
allows for the growth of spheroids, this allows for a 3D structure to be made and reflects the 
complex in vivo microenvironment better than 2D (Vinci 2012). There were no large differences in 
the mean spheroid sizes for any of the observed samples. However, the 9-day time point for the 
PcTF expressing cell line in Figure 4.4B showed a large difference in the mean sizes with the 
untreated samples (7903𝜇m2) and the dox treated (11,138	𝜇m2). Image segmentation was carried 
out using imageJ; areas of interest were randomly selected from five different regions and 20 
different spheroids were measured in each region. Each bar represents 100 samples measured 
over nine days.  
                           
Figure 4.5 Invasion growth assay with induced PcTF. Cells were grown on a gel matrix with columns 
punched into them to allow seeding of cells into these wells. Cells were grown for four days under 
treated or untreated dox conditions where the presence of dox induces expression of PcTF. 
 Next, the same PcTF transgenic MCF7 cell line was used to measure growth and 
invasiveness when under dox treated and untreated conditions. Both plates were seeded with an 
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equal number of cells and were grown on a gel matrix that contained small wells in which the sells 
would be added. In Figure 4.5 cells from untreated and treated were imaged for GFP and RFP and 
on day one both conditions had similar colony sizes. However, on day 4 the size of the untreated 
cell line shows colonies larger than those of the PcTF expressing colonies. This is contradicting 
what was seen in Figure 4.4, where PcTF expressing mass sizes were growing at a similar rate up 
until day 9. This could have been due to the different culturing condition and the sheering forces of 
the shaking condition versus the sedimentary growth conditions used in the invasion assay. 
 Conclusions: With the increase in the spheroid growth in the dox treated PcTF cell line 
there are several different additional experiments that need to be done to answer new questions. 
Is it the number of cells in the spheroid that is changing the size or is it the size of the individual cell 
itself that is changing? There is the potential to collect the measure spheroid populations and 
disassociate the sphere to be run through flow cytometry to see if there is a shift in the overall sizes 
of the cells between the untreated and treated PcTF cell lines on day 9 of growth. If the average 
cell size is larger in the PcTF samples, we will know that the increase in spheroid size is due to the 
individual cells becoming larger and not the increased proliferation of the cells. RT-qPCR could 
also be run to look at housekeeping genes and other genes related to control of cell division and 
also proto-oncogenes such as NRAS and BRAF (Kumar, 2019). This experiment requires further 
analysis regarding the health of the spheroids. The invasion assay would also require extra time to 
determine if the 9-day timepoint shows the increased growth rate since this assay was only carried 
out for four days. In addition,  a control treatment should be utilized, the use of a drug that could 
slow the growth of MCF7, and should ensure that anti-tumor activity can be observed when 
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